NCT01450241

Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia

Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Rabin Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether short-course antibiotic therapy is safe and effective for the treatment of cancer patients with febrile neutropenia.

Detailed description

Febrile neutropenia remains a major cause of morbidity in solid cancer patients. There is an unresolved question regarding the appropriate duration of antibiotic treatment for patients with febrile neutropenia of unknown origin. Current guidelines recommend at least seven days of antibiotic treatment. Several studies have demonstrated the safety of early antibiotic discontinuation in patients with febrile neutropenia. We plan an open label randomized controlled trial to compare early antibiotic discontinuation to the accepted prolonged antibiotic treatment protocol

Conditions

• Febrile Neutropenia

Interventions

Type	Name	Description
OTHER	Early antibiotic discontinuation	Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
OTHER	Usual practice	Continued antibiotic treatment as accepted by guidelines for febrile neutropenia

Timeline

• Start date: 2012-01-01
• Primary completion: 2014-01-01
• Completion: 2015-01-01
• First posted: 2011-10-12
• Last updated: 2013-06-07

Locations

1 site across 1 country: Israel